GET DAILY SIGNALSHealthpeak Properties (DOC) Reports +16.3% Revenue Growth in Q3 2026
Key Takeaways
- Healthpeak Properties (DOC) reported third quarter 2026 net income of $0.02 per share and Funds From Operations (FFO) as Adjusted of $0.44 per share.
- Total revenue reached $820.89 million, up 16.3% year over year and ahead of the roughly $758 million consensus estimate.
- FFO as Adjusted of $0.44 per share edged past the $0.43 consensus, while same-store net operating income (NOI) grew 3.6% year over year.
- The company raised its full-year 2026 FFO as Adjusted guidance, reflecting strength in its senior housing and lab segments.
- Majority-owned Janus Living posted revenue growth of 78% and Adjusted EBITDAre growth of 101% year over year.
The Broader Picture for These Results
Healthpeak Properties is a real estate investment trust (REIT) and S&P 500 company focused on healthcare discovery and delivery, spanning outpatient medical buildings, life science labs, and senior housing. Its third quarter 2026 results arrive at a pivotal moment, as the company continues integrating its majority stake in Janus Living following that entity's initial public offering (IPO) earlier in 2026. Investors are watching closely because Healthpeak's diversified healthcare portfolio now blends stable outpatient medical cash flows with faster-growing senior housing and a recovering lab segment. The quarter's lease execution figures, same-store growth, and updated guidance offer a clear read on demand across each business line, making this release a key barometer for the healthcare real estate sector's trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Quarter's Numbers
For the quarter ended September 30, 2026, Healthpeak reported diluted net income of $0.02 per share, compared with a net loss of $0.17 per share in the prior-year period. Diluted FFO as Adjusted, a key profitability metric for REITs that excludes real estate depreciation and certain non-recurring items, came in at $0.44 per share, down modestly from $0.46 a year earlier but above the $0.43 consensus estimate. Total revenue of $820.89 million rose 16.3% year over year and surpassed the approximately $758 million consensus.
Same-store adjusted NOI grew 3.6% overall, led by a 25.9% increase in senior housing. Outpatient medical same-store NOI rose 3.1%, while the lab segment declined 0.7%. Notably, lab occupancy increased 130 basis points (bps) sequentially and 270 bps since year-end 2025, signaling gradual stabilization. Janus Living contributed revenue of $268 million, up 78% year over year, with Adjusted EBITDAre up 101%.
Market Reaction and Investor Sentiment
Healthpeak shares have drawn mixed sentiment in recent weeks, with the stock down roughly 2.4% over the past month heading into the report, according to market data. The earnings release and increased full-year FFO guidance provide a constructive backdrop, particularly given the strength in senior housing and the sequential improvement in lab occupancy. However, investors remain attentive to the lower diluted earnings-per-share guidance, which reflects higher depreciation and amortization from Janus Living's senior housing acquisitions. The post-earnings conference call will likely shape near-term sentiment as management elaborates on leasing momentum and capital allocation priorities.
Forward Outlook and Key Factors to Monitor
Healthpeak raised its full-year 2026 diluted FFO as Adjusted guidance to a range of $1.76 to $1.78 per share, a $0.02 midpoint increase, while lifting its total same-store cash adjusted NOI growth outlook to 0.5% to 2.0%. At the same time, diluted earnings-per-share guidance moved lower to $0.39 to $0.41, reflecting depreciation and amortization tied to senior housing acquisitions.
Investors should monitor several catalysts in the coming quarters. First, lab leasing activity remains a central theme; the company executed 480,000 square feet of lab leases in the quarter and has an additional 643,000 square feet executed or under letter of intent. Continued occupancy gains could support same-store NOI recovery in that segment.
Second, Janus Living's acquisition pipeline is a key growth driver. The entity closed $1.75 billion of senior housing acquisitions during the quarter and roughly $370 million more through late October. How quickly these properties contribute to earnings and whether the favorable senior housing supply-demand backdrop persists will matter for consolidated results.
Finally, balance sheet and cost trends deserve attention. Net debt to Adjusted EBITDAre stood at 4.7x, and the company entered a new $500 million delayed-draw term loan facility, leaving it with $3.8 billion of liquidity. Interest rate movements and refinancing costs will influence future FFO growth, while the recently declared monthly dividend of $0.10167 per share (an annualized $1.22) underscores management's commitment to shareholder distributions. From what I see, this is important because it highlights the company's focus on maintaining flexibility amid shifting rates.
Using AI Tools in My Research Process
In my ongoing analysis of healthcare REITs like DOC, I often turn to Tickeron’s AI Screener to quickly filter opportunities based on fundamentals, technical patterns, and sector trends. It helps surface comparable names and validate ideas without spending hours on manual screens. This kind of tool fits naturally into a broader workflow when evaluating earnings releases and guidance updates, giving a clearer view of relative positioning across the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DOC's RSI Oscillator recovers from oversold territory
The RSI Indicator for DOC moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 24 of the 34 cases the stock moved higher. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on DOC as a result. In 51 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for DOC just turned positive on October 20, 2026. Looking at past instances where DOC's MACD turned positive, the stock continued to rise in 21 of 41 cases over the following month. The odds of a continued upward trend are 51%.
Following a +2.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOC advanced for three days, in 148 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 66 cases where DOC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
DOC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DOC entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. DOC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.712) is normal, around the industry mean (3.125). P/E Ratio (55.657) is within average values for comparable stocks, (28.561). DOC's Projected Growth (PEG Ratio) (4.319) is slightly higher than the industry average of (1.649). Dividend Yield (0.021) settles around the average of (0.049) among similar stocks. P/S Ratio (4.787) is also within normal values, averaging (6.013).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a real estate investment trust
Industry PublishingBooksMagazines
Advertisement